15 April 2013Americas

Supreme Court to hear oral arguments in Myriad case

Myriad Genetics will deliver an oral argument at the US Supreme Court today (Monday, April 15) defending its patents covering isolated human gene sequences linked to breast and ovarian cancer.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Australia: the Myriad case

1 February 2013 The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues.

Myriad: Keeping a low profile

1 December 2012 The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

More on this story

Australia: the Myriad case

1 February 2013 The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues.

Myriad: Keeping a low profile

1 December 2012 The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

More on this story

Australia: the Myriad case

1 February 2013 The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues.

Myriad: Keeping a low profile

1 December 2012 The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims